Topiramate Tablet
Product Images NDC 69097-818

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 69097-818). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimates Of Cumulative Rates For Time To First Seizure (Topiramate Fig1)

The given text shows cumulative rates for time to first seizure for two groups of patients receiving different doses of a drug called Topiramate. The first group received a daily dose of 50 mg (N=23), while the second group received a higher dose of 400 mg/day (N=236). Unfortunately, the rest of the text is not available.*

FDA Label Image

Table 12: Efficacy Results In Double-blind, Placebo-controlled, Add-on Epilepsy Trials (Topiramate Fig2)

This appears to be a table of data related to the drug Topiramate. The table lists the dosages (50mg/day, 100mg/day, 200mg/day) and the number of participants in the study for each dosage. The table also includes a statistical measure denoted by "*p" and "**p" for different dosages, which likely indicates the significance of any observed effects for that particular dosage.*

FDA Label Image

Topiramate Fig3 Inv

This is a prescription drug with the NDC code 69097-816-03, indicated for the treatment of epilepsy and migraine. It is a tablet containing 25 mg of USP topiramate manufactured by InvaGen Pharmaceutical, a subsidiary of Cipla Ltd. The tablets come in a bottle of 60 and should be dispensed with an attached medication guide. The prescribing information is included in the accompanying literature. It should be stored in a tight container at a controlled room temperature of 20° to 25°C (68° to 77°F) to protect from moisture. The drug was manufactured for Cipla USA, Inc. and was last reviewed on May 12, 2020.*

FDA Label Image

Topiramate Fig4 Inv

This is a description of a medication called Topiramate, USP. It is dispensed as a pack of 60 tablets and each tablet contains 50 mg of topiramate, USP. It is manufactured by InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) and distributed by Cipla USA, Inc. It comes with an attached medication guide and should be stored at controlled room temperature (20° to 25°C), protected against moisture. The lot number and expiry date is indicated on the pack. The text also contains a prescription warning that denotes Rx Only.*

FDA Label Image

Topiramate Fig5 Inv

This is a description of a medication named Topiramate, available in tablet form with a dosage of 100 mg. It is a prescription-only medication that should be stored at room temperature in a container that protects it from moisture. The medication should be dispensed with an attached medication guide. The manufacturer of the medication is Invagen Pharmaceuticals, Inc. and it was distributed by Cipla USA, Inc. The packaging contains 60 tablets and the lot number is J000000000X. The text does not contain any further information.*

FDA Label Image

Topiramate Fig6 Inv

Topiramate Tablets USP is a prescription drug that comes in a pack of 60 tablets, with each tablet containing 200 mg of topiramate. These tablets should be dispensed in a tight container and protected from moisture. The medicine has been manufactured by InvaGen Pharmaceuticals, Inc, a subsidiary of Cipla Ltd, located in Hauppauge, NY. For additional information, refer to the attached medication guide.*

FDA Label Image

Chemical Structure (Topiramate Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.